JPRN-jRCT2080221710未知1 期
Drug-drug interaction study (2) of Tofogliflozin (CSG452) in healthy adult male volunteers
试验速览
- 阶段
- 1 期
- 入组人数
- 87
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 45age old（—）
- 性别
- Male
入选标准
- •healthy volunteers
- •-Body mass index (BMI) >=18.5 kg/m2 and <25.0 kg/m2
- •-eGFR >= 90 mL/min/1.73 m2
- •-Has not smoked for at least a year before screening and will not smoke during the study period
排除标准
- •Has been administered any of the medicines, foods and drinks that can affect the pharmacokinetics of Tofogliflozin or concomitant drugs to be tested for drug-drug interactions within two weeks before administration in Period I
研究者
相似试验
未知
1 期
Drug-drug interaction study (1) of TofoglifloziType 2 diabetsJPRN-jRCT2080221599Chugai Pharmaceutical Co., Ltd.90
未知
2 期
Clinical Pharmacology Study of Tofogliflozin --Evaluation of influence by degree of kidney functionType 2 diabetesJPRN-jRCT2080221532Chugai Pharmaceutical Co., Ltd.40
未知
1 期
Clinical pharmacology study of Tofogliflozin in patients with hepatic impairmentType 2 diabetesJPRN-jRCT2080221650Chugai Pharmaceutical Co., Ltd.16
已完成
不适用
Comparison of safety and efficacy of Tofogliflozin and Ipragliflozin in patients with type 2 diabetestype 2 diabetesJPRN-UMIN000037158Minami Osaka hospital24
招募中
4 期
Effect of tofogliflozin on pancreatic beta-cell functioType 2 diabetesJPRN-jRCTs011230006akamura Akinobu70